In one of their reports, 2 out of 3 refractory CLL patients receiving CD19 CAR T cells therapy achieved complete response (CR), and another patient demonstrated partial response (PR) [4]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.